Endocrine therapy or chemotherapy as first-line therapy in hormone receptor –positive HER2-negative metastatic breast cancer patients
For hormone receptor –positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines recommend endocrine therapy as first-line treatment, except in case of ‘visceral crisis’. In the latter case, chemotherapy is preferred. Few studies have compared these two strategies. We used the Epidemiological Strategy and Medical Economics (ESME) programme, UNICANCER, a large national observational database (NCT03275311), to address this question.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: E. Jacquet, A. Lardy-Cl éaud, B. Pistilli, S. Franck, P. Cottu, S. Delaloge, M. Debled, L. Vanlemmens, M. Leheurteur, A.V. Guizard, L. Laborde, L. Uwer, W. Jacot, D. Berchery, I. Desmoulins, J.M. Ferrero, G. Perrocheau, C. Courtinard, E. Brain, S. Chabau Tags: Original Research Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Economics | Endocrine Therapy | Epidemiology | HER2 | Hormones | Neurology | Study